Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    " April 22, 2009":" May 22, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" April 22, 2009":" May 22, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: ADVAX;   Biological: TBC-M4;   Other: Placebo
2 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine
3 Completed HIV- Risk Reduction Behavioral Intervention for Commercial Sex Workers in Yerevan Armenia
Conditions: HIV Prevention;   HIV Infections
Intervention: Behavioral: HIV risk reduction intervention
4 Active, not recruiting Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Conditions: HIV Infections;   Memory
Intervention:
5 Completed Linkage to Care - Part II
Conditions: HIV;   Care-seeking;   HIV Infections
Interventions: Other: Case Management;   Other: Snowball sampling;   Other: Referral Lists
6 Unknown  Raltegravir in the Swiss HIV Cohort Study
Condition: HIV Infection
Intervention: Drug: Raltegravir
7 Completed Empowerment Intervention for Young Women - Phase I
Conditions: HIV;   Empowerment;   HIV Infections
Intervention: Behavioral: Prevention Empowerment Intervention for Young Women
8 Completed TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
Condition: HIV Infections
Intervention: Drug: TMC207; nevirapine
9 Unknown  Cognitive and Psychosocial Benefits of MISC Training for Ugandan Children
Conditions: HIV;   HIV Infections
Intervention: Behavioral: MISC training for primary caregivers
10 Withdrawn PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.
Condition: HIV Infections
Interventions: Drug: TMC589337 40 mg;   Drug: TMC589337 100 mg;   Drug: TMC589337 200 mg;   Drug: TMC589337 400 mg;   Drug: TMC589354 40 mg;   Drug: TMC589354 100 mg;   Drug: TMC589354 200 mg;   Drug: TMC589354 400 mg;   Drug: TMC589337 AA mg;   Drug: TMC589354 BB mg;   Drug: TMC589337 CC mg;   Drug: TMC589354 DD mg;   Drug: TMC589337 EE mg;   Drug: TMC589354 YY mg;   Drug: TMC310911 300 mg;   Drug: TMC310911 600 mg;   Drug: Placebo
11 Completed
Has Results
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
Condition: HIV Infections
Interventions: Drug: Nevirapine Immediate Release (IR);   Drug: Nevirapine Extended Release (XR)
12 Unknown  HIV and Kidney Function Study
Conditions: HIV Infections;   AIDS
Intervention:
13 Completed Hepatitis B Vaccination (HBV) in HIV Infected Children
Condition: HIV Infections
Interventions: Biological: Intradermal HBV 1 course;   Biological: Intramuscular HBV I course
14 Completed Prevalence and Determinants of Chronic Obstructive Pulmonary Disease (COPD) in HIV+ Patients
Conditions: HIV Infections;   COPD
Intervention:
15 Completed
Has Results
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Atazanavir (ATV) 300 mg;   Drug: Atazanavir (ATV) 400 mg;   Drug: Ritonavir (rtv) 100 mg;   Drug: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs);   Drug: Etravirine (ETR) 200 mg;   Drug: Tenofovir disoproxil fumarate (TDF) 300 mg
16 Completed
Has Results
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Conditions: Hypercholesterolemia;   HIV Infections
Interventions: Drug: Ezetimibe;   Drug: Rosuvastatin (standard care)
17 Completed Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid
Conditions: Human Immunodeficiency Virus Infections;   HIV Infections
Interventions: Biological: tgAAC09;   Other: Formulation buffer
18 Completed Efficacy and Safety of Single Versus Double Ritonavir-Boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: ritonavir-boosted PI-based second line treatments;   Drug: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
19 Completed
Has Results
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
Conditions: Anxiety Disorders;   HIV Infections
Intervention: Drug: Escitalopram
20 Completed
Has Results
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
Conditions: HIV Infection;   HIV;   Acquired Immunodeficiency Syndrome
Interventions: Drug: etravirine (ETR, TMC125);   Drug: efavirenz (EFV)

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.